CYPH

Cypherpunk Technologies Inc.
NASDAQFINANCIAL SERVICESASSET MANAGEMENT

Key Statistics

Market Cap
$76.01M
P/E Ratio
0.99
EPS
$0.71
Beta
0.06
52W High
$3.70
52W Low
$0.26
50-Day MA
$0.68
200-Day MA
$0.92
Dividend Yield
Profit Margin
0.00%
Forward P/E
PEG Ratio

About Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. The company is headquartered in Cambridge, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)0
Gross Profit (TTM)0
EBITDA$-36.69M
Operating Margin0.00%
Return on Equity-1.21%
Return on Assets-13.80%
Revenue/Share (TTM)$0.00
Book Value$1.29
Price-to-Book0.50
Price-to-Sales (TTM)160.10
EV/Revenue-
EV/EBITDA49.18
Quarterly Earnings Growth (YoY)0.00%
Quarterly Revenue Growth (YoY)0.00%
Shares Outstanding$107.76M
Float$91.44M
% Insiders8.34%
% Institutions21.31%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Latest News

Cypherpunk Technologies Launches World's Largest Zcash Mining Fleet

Equity-based transaction with Winklevoss Capital activates 4.2 GSol/s of live, U.S.-based hashrate; approximately 18% of the Zcash network; Industry veteran Kevin Zhang joins as Head of Mining CAMBRIDGE, Mass., Aug. 18, 2026 /PRNewswire/ -- Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk") today announced the launch of Cypherpunk Mining, which is now the largest Zcash mining fleet in the world, through a $33.33 million equity-based transaction with Winklevoss Capital.

PRNewsWire8/18/2026Neutral
Leap Therapeutics Announces Publication of DeFianCe Study Results in Clinical Cancer Research

Peer-reviewed analyses establish baseline plasma DKK1 as a continuous quantitative biomarker predicting deepening sirexatamab benefit in 2L mCRC patients In DKK1-high 2L mCRC patients, sirexatamab improved response, progression-free survival, and overall survival when added to bevacizumab and chemotherapy CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ -- Leap Therapeutics, Inc., the biotechnology subsidiary of Cypherpunk Technologies Inc. (Nasdaq: CYPH), today announced the publication of results from the randomized Phase 2 DeFianCe study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research.

PRNewsWire8/12/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CYPH and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More FINANCIAL SERVICES Stocks

Data last updated: 8/18/2026